As the number of new MS therapies continues to grow, so does the uncertainty about which management approach — escalation or highly effective disease-modifying therapy — is best for each patient. What are the patient-specific factors that indicate the most appropriate DMT selection? What’s known about the potential longer-term risks associated with highly effective therapies? 

That’s the focus of our discussion with Dr. Yujie Wang from the University of Washington and Johns Hopkins University, and Dr. Anne Damian-Yacoub from Johns Hopkins University in this eMultipleSclerosis Review podcast. 

Take our post-test to claim CME credits.

To read a companion newsletter click here.

Hosted on Acast. See acast.com/privacy for more information.